BMRN Biomarin Pharmaceutical
- 82.440
- -1.360-1.62%
- 82.600
- +0.160+0.19%
Biomarin Pharmaceutical News
Biomarin Pharmaceutical | 8-K: BioMarin Reports Record Financial Results for the First Quarter 2024
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | DEF 14A: Definitive information statements
Biomarin Pharmaceutical | DEFA14A: Others
Biomarin Pharmaceutical | 8-K: BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Biomarin Pharmaceutical | 8-K: BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
Biomarin Pharmaceutical | 8-K: BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues • Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 202
Biomarin Pharmaceutical | DEFA14A: Others
Biomarin Pharmaceutical | DEF 14A: Definitive proxy statements
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 8-K: Current report
Analysis
Price Target
No Data
